The pre CISION tech is simply an attempt to improve the safety profile... 2/10
AVA6000 approved by MHRA. Superb news. First dosing 'around mid-year'; first data to come within 3-4 months after that.
A summary thread on the significance of AVA6000 - and #AVCT's pre CISION platform as a whole - to both the oncology industry and to AVCT itself. 1/10
The pre CISION tech is simply an attempt to improve the safety profile... 2/10
Most therapeutics going through clinical trials look for an improvement of at least 20% over the existing industry-standard drug. A 50% increase in efficacy would usually be considered an astonishing result.
In pre-clinical mouse models for #AVCT's AVA6000 3/10
What this means is that the pre CISION tech could be used to enable the giving of doses to patients that are multiple times more potent... 4/10
For example, in #AVCT's pre-clinical trials, pro-dox (AVA6000) doses were 6x more potent than the standard dox doses.
The results? The...5/10
#AVCT isn't looking to improve chemotherapies by 25-30%, like most drugs in clinical trials.
Its pre CISION has the potential to improve the safety profile - and thus the... 6/10
https://t.co/XOEE45CBtZ
AVCT holds the global exclusive licence over...8/10
TMAC will produce Affimer Drug Conjugates - a potentially more powerful class of oncology treatment than Antibody Drug Conjugates. 9/10
First though, success for AVA6000 please!
Then hopefully @avacta's first TMAC drug to enter Phase I next year 10/10
More from Society
Krugman is, of course, right about this. BUT, note that universities can do a lot to revitalize declining and rural regions.
See this thing that @lymanstoneky wrote:
And see this thing that I wrote:
And see this book that @JamesFallows wrote:
And see this other thing that I wrote:
One thing I've been noticing about responses to today's column is that many people still don't get how strong the forces behind regional divergence are, and how hard to reverse 1/ https://t.co/Ft2aH1NcQt
— Paul Krugman (@paulkrugman) November 20, 2018
See this thing that @lymanstoneky wrote:
And see this thing that I wrote:
And see this book that @JamesFallows wrote:
And see this other thing that I wrote: